The ret transforming gene was activated by recombination between two unlinked segments of human DNA, most likely during transfection of NIH 3T3 cells. To further define this transforming gene, we isolated and sequenced ret cDNA clones. The nucleotide sequence indicates that the active ret transforming gene encodes a fusion protein with a carboxy-terminal domain which is 40 to 50% homologous to members of the tyrosine kinase gene family. This tyrosine kinase domain is preceded by a hydrophobic sequence characteristic of a transmembrane domain. Transcription of the ret tyrosine kinase sequence was detected in the SK-N-SH neuroblastoma, HL-60 promyelocytic leukemia, and THP-1 monocytic leukemia cell lines, but not in 25 other human tumor cell lines surveyed. The ret tyrosine kinase may thus represent a cell surface receptor which is expressed in a restricted range of human cells.
The ret transforming gene was detected by transfection of NIH 3T3 cells with DNA of a human T-cell lymphoma (22) . This lymphoma DNA yielded only a single focus in primary transfection assays (corresponding to approximately 0.003 transformants per ,ug of DNA), whereas transformed NIH cell DNAs induced transformation with high efficiencies (approximately 0.5 transformants per ,ug of DNA) in secondary and tertiary transfection assays (22) . The ret gene was cloned from transformed NIH cells by hybridization with human repetitive sequence probes (22) . Analysis of the cloned sequence indicated that the active ret transforming gene encompassed approximately 34 kilobases (kb) of human DNA and was generated by recombination of two DNA segments (each approximately 17 kb) which were unlinked in DNA of either normal human cells or the T-cell lymphoma which gave rise to the initial focus of transformed NIH cells (22) . Both segments of ret were cotranscribed in transformed NIH cells, indicating that the transforming gene had been activated by a recombination event which generated a new transcriptional unit (22) . The low primary transforming efficiency and the absence of rearranged ret sequences in the original lymphoma DNA suggested that ret represented a normal human gene whose transforming potential was activated by a DNA rearrangement during transfection (22) .
To further characterize the recombination event which resulted in ret activation, we cloned and sequenced a ret cDNA. Analysis of this cDNA sequence indicated that ret encodes a fusion protein, the carboxy-terminal half of which is a new member of the tyrosine kinase family.
MATERIALS AND METHODS
Cell lines. NIH 3T3 cells transformed by ret in tertiary transfections were previously described (22) (Fig. 2A) . The 12.4-and 7.8-kb BamHI fragments in NIH transformant DNA represent the left-hand human segment and the recombined region of ret, respectively (22) . The 19.0-and 12.4-kb BamHI fragments of human DNA correspond to the lefthand segment of ret, and the 3.9-kb fragment corresponds to the right-hand segment (22) . The 19.0-and 3.9-kb BamHI fragments of human DNA recombined to generate the 7.8-kb BamHI fragment of the active ret gene (22) . Fragment C of the ret cDNA thus includes the left-hand segment of ret, the recombination site, and some sequence from the right-hand segment.
Fragment D of ret cDNA hybridized to the 7.8-kb BamHI fragment in DNA of transformed NIH cells and to the 3.9-kb BamHI fragment in human DNA (Fig. 2B) Sequence of ret cDNA. The inserts of lambda ret-i and lambda ret-2 were subcloned in pBR322, and their complete nucleotide sequence was determined by the Maxam-Gilbert method (11) by using the strategy shown in Fig. lb Homology of ret to tyrosine kinases. The homologous region of the predicted ret amino acid sequence is aligned with those of the tyrosine kinase family members ros (13) , abl (17) , src (19) , fms (5), fps (21), human insulin receptor (HIR) (23) , and human epidermal growth factor receptor (HER) (24) . Numbers refer to the ret amino acid sequences. Amino acid identities are enclosed in boxes.
terminus) to the termination codon TAG at nucleotide 2416. This termination codon is followed by 67 nucleotides of 3' untranslated region and about 100 nucleotides of poly(A). The sequence does not contain a consensus polyadenylation signal (AATAAA), suggesting that the longer species of ret mRNA may extend further 3'. Since the total length of the cDNA sequence is less than that of the smallest ret mRNA, the ret coding sequence may also extend farther in the 5' direction. The sequence indicates that ret has the capacity to encode a protein of at least 800 amino acids. This predicted gene product represents a fusion protein containing recombined coding sequence from both the left-hand (5') and right-hand (3') human segments of the ret gene, since the site of recombination is between the XhoI (nucleotide 406) and BamHI (nucleotide 1077) sites which define the termini of cDNA fragment C. region of the 3' portion of ret from amino acids 455 to 732 (underlined in Fig. 3 ) derived from the right-hand human segment forming the ret gene displayed significant homology to members of the tyrosine kinase gene family.
Analysis of this 278-amino acid domain of ret revealed 40 to 50%o homology with other tyrosine kinases including ros (13) , abl (17) , src (19) , fms (5), fps (21) , human insulin receptor (23) , and human epidermal growth factor receptor (24) (Fig. 4) . In addition, it showed similar homology with other recently identified tyrosine kinases including Isk+ (9), met (3), neu (1), kit (2) , and trk (10) . The homology of ret to these tyrosine kinases includes the lysine thought to be involved in ATP binding (6) (ret amino acid 491) and a putative phosphotyrosine acceptor site (16) (ret amino acid 638). However, the ret sequence is not identical to the sequences of these or any other members of the tyrosine kinase family. Rather, the extent of homology of ret to the amino acid sequences of these tyrosine kinases is similar to that between the different members of this family and does not suggest a closer relationship of ret to any particular family member.
The predicted ret amino acid sequence also includes a stretch of 22 hydrophobic amino acids (369 to 390) which is bounded by basic amino acids and could serve as a membrane-anchoring domain (18) . Similar transmembrane domains are found in the other tyrosine kinases which are known cell surface receptors, including the insulin (23) and epidermal growth factor receptors (24) and fms (colonystimulating factor 1 receptor) (5, 20) , as well as in ros (13) , trk (10) , and neu (1 (Fig. 5A and B, lanes b) . In addition, ret cDNA fragment C hybridized to less abundant transcripts of approximately 2.4 and 3.4 kb in poly(A)+ RNAs of each of 17 human tumor cell lines tested (representative results in Fig. SA, lanes c to m) . An additional faint band of about 5 kb was also detected in some samples but may represent nonspecific hybridization to 28S rRNA. The human sequence corresponding to the 5' portion of ret was thus transcribed in a wide variety of different human tumor cell lines.
When fragment E of the ret cDNA was used as a probe, four transcripts (7.0, 6.0, 4.5, and 3.9 kb) were observed in poly(A)+ RNAs of THP-1 (monocytic leukemia), (promyelocytic leukemia), and SK-N-SH (neuroblastoma) cell lines (Fig. 5B, lanes h, i, and n) . The These results indicate that the 3' sequence of ret, which contains the tyrosine kinase domain, is expressed only in restricted human cells.
DISCUSSION
The activated ret transforming gene was generated, apparently during transfection of NIH 3T3 cells, by recombination between two unlinked segments of human DNA (22) . Analysis of the nucleotide sequence of ret cDNA indicates that this recombination event generated a fusion protein with a coding sequence derived from both of the human DNA segments which form the active ret gene. The aminoterminal half of ret is unrelated to other known amino acid sequences, but the carboxy-terminal half is 40 to 50% homologous to members of the tyrosine kinase gene family, including a variety of retroviral transforming genes, the cell surface receptors for insulin and epidermal growth factor, and the cellular transforming genes met, neu, and trk. Thus, ret appears to be a new member of the tyrosine kinase gene family whose transforming potential was activated by fusion of a carboxy-terminal kinase domain with previously unlinked amino-terminal sequences.
Activation of the transforming potential of the ret tyrosine kinase by gene fusion is reminiscent of the mode of activation of several other tyrosine kinases, including the epidermal growth factor receptor gene in avian erythroblastosis virus (erbB) (4), the fgr gene of Gardner-Rasheed feline sarcoma virus (12) , the abl gene in both Abelson leukemia virus (26) and chronic myelogenous leukemia (7), and the human transforming genes met (15) and trk (10) . In each of these cases, transforming potential is activated by a recombination event which results in deletion of the normal amino-terminal domain of a tyrosine kinase. These observations thus suggest that a variety of tyrosine kinases contain amino-terminal regulatory domains, the loss of which can result in abnormal enzymatic activity leading to cell transformation.
The predicted ret amino acid sequence contains a hydrophobic region of 22 amino acids which is bounded by basic amino acids and is located approximately 65 amino acids before the beginning of the tyrosine kinase domain. This hydrophobic region is typical of transmembrane domains (18) , and its location in the ret sequence is similar to the location of transmembrane domains in those tyrosine kinases (fms, epidermal growth factor receptor, and insulin receptor) which are known growth factor receptors (5, 23, 24) . This suggests that the normal ret tyrosine kinase is a cell surface receptor for a currently unidentified molecule. Since transcription of the ret tyrosine kinase domain was detected in only 3 of 28 human tumor cell lines surveyed, it is possible that the ret tyrosine kinase is a receptor which normally functions in restricted stages or lineages of differentiation rather than in a wide variety of cell types.
